Global Biosimilars Market

Home Healthcare And Pharmaceutical Global Biosimilars Market

Biosimilars Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Product (Monoclonal Antibodies (Infliximab, Rituximab, Trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin); By Disease Indication (Cancer, Auto Immune Diseases, Chronic Diseases, Blood Disorders, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region (North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA))

Published Date: November 2022
Report ID: BWC22532
Available Format: PDF
Page: 240

Report Overview

Rising prevalence of autoimmune diseases, rising adoption of cost-effective biosimilars, patent expiry on many blockbuster biological drugs, and rising government spending on healthcare could boost the growth of Global Biosimilars Market at a robust growth rate during the forecast period between 2023 and 2029.

Global Biosimilars Market - Industry Trends & Forecast Report, 2029

Global biosimilars market size is estimated at USD 28.88 billion in 2022. During the forecast period between 2023 and 2029, the size of global biosimilars market is projected to grow at a CAGR of 21.3%, reaching a value of USD 115.39 billion by 2029. The growth of the global biosimilars market is being driven by the biosimilars' affordability in treating a variety of chronic diseases that are common among the world's population. The adoption of biosimilars is expected to increase quickly due to the rising prevalence of chronic diseases among the population and the recent approval of numerous biosimilars in many countries by regulatory authorities. The demand for biosimilars is increasing globally due to growing awareness of the availability of biosimilar medications and their efficacy in treating a variety of disorders. Biosimilars are an effective treatment option for several chronic diseases, including kidney failure, diabetes, cancer, and cardiovascular disease, which is expected to fuel the growth of global biosimilars market during the period in analysis.

Global Biosimilars Market

Global Biosimilars Market- Overview

A biotherapeutic product that is similar to a reference biologic drug is referred to as a biosimilar, also known as a follow-on biologic. It has a complex molecular structure and is made from living things or cells. Manufacturers rely on regulatory authority approval to launch the production of biosimilars after the patent on a biologic drug expires. A biological drug must be demonstrated to be similar in terms of quality, safety, and efficacy to be labeled as a biosimilar. Biosimilars are more expensive than generic medications because their production requires greater investment in R&D and is more complicated.

Growth Drivers

Cost-effectiveness of biosimilars

Increased demand for biosimilars will promote business growth in the future. The American Journal of Managed Care (AJMC) reports that biosimilar drugs are priced 20% to 30% lower than reference biologic drugs. According to the AJMC study, the use of these drugs will result in USD 102.5 billion in savings between 2014 and 2025. Their lower cost of results in effective patient treatment as well as treatment cost-cutting will be a major growth factor. Furthermore, price competition between follow-on biologics and reference drugs has a downward effect on the prices of reference biologics, thereby accelerating business growth.

Rising proficiencies in R&D

Rising R&D spending, particularly in developed and developing economies, will create more lucrative market growth opportunities for drugs, medical instruments, and devices. R&D abilities have resulted in advancements in medical technology and an improvement in the quality of healthcare facilities. The growing number of screening tests for research abilities has broadened the scope of growth even further. In the coming years, it is expected that regulatory reforms in major countries, including the US, China, and Japan, will increase the adoption of biosimilars. Over 60 biosimilar brands have already received European approval, which make up about 50% of the market. Seven biosimilars were given US FDA approval in 2018. Because of this, it is expected that regulatory reforms in the key markets will have a positive effect on market growth and offer the market's players lucrative opportunities for future growth. Additionally, the key players in the market are increasing their investments in R&D, which is fueling innovation in the global biosimilars market. New opportunities are opening as the patents on older biosimilar medications expire.

Restraints

High cost of R&D

Excessive costs associated with R&D capabilities, high manufacturing costs, and difficulties associated with medical procedures are anticipated to limit the growth of global biosimilars market. In addition, a lack of favorable reimbursement scenarios and technology penetration in developing economies, as well as a lack of definitive approval standards and suitable infrastructure in low- and middle-income countries, are anticipated to pose challenges to the market growth during the forecast period.

Impact of COVID-19 on Global Biosimilars Market

The COVID-19 outbreak had an impact on several global industries, and the biosimilars market is no exception. To slow the Covid-19 pandemic's rapid spread, administrative bodies worldwide implemented several measures, including lockdowns and strict social seclusion. The global closure of manufacturing facilities during the early stages of the pandemic hurt the biosimilars market. Small and medium-sized businesses, which are the main technology suppliers to the biosimilars industry, saw a sharp decline due to the pandemic. The restricted movement of people and goods because of the lockdown measures put in place during the early stages of the pandemic's spread also had an impact on the global biosimilars market. However, during the post COVID-19 pandemic period, the global market for biosimilars is expected to grow at an impressive growth rate as biosimilars provide significant cost savings to government and third-party payors.

Global Biosimilars Market

Segmental Coverage

Global Biosimilars Market - By Product

Global biosimilars market is divided into Monoclonal Antibodies (Infliximab, Rituximab, Trastuzumab), Insulin, Interferon, Etanercept, Glucagon, and Calcitonin. In 2021, the monoclonal antibodies market share was greater than 25%. Numerous illnesses, including cancer, rheumatoid arthritis, cardiovascular diseases, and multiple sclerosis, are treated with the help of monoclonal antibodies. Due to the widespread use of monoclonal antibodies in the treatment of cancer, which specifically targets specific infected cells, the Monoclonal Antibodies segment is expected to maintain its leadership position during the forecast period.

Global Biosimilars Market Share

Global Biosimilars Market - By Disease Indication

On basis of the disease indication, global biosimilars market is divided into Cancer, Auto Immune Diseases, Chronic Diseases, Blood Disorders, and other segments. The global market is expanding as chronic diseases are becoming more common. A growing number of people around the world are using biosimilar medications because of their affordability. During the forecast period, an increase in the number of cancer patients, chronic disease cases, and geriatric population growth are expected to drive up demand for biosimilars.

Over 70% of cancer deaths occur in low- and middle-income countries, making it the second leading cause of death worldwide. Age-related increases in cancer incidence are most likely caused by an increase in the risk of developing particular cancers as people age. In the coming years, the development of biosimilar medications for the treatment of chronic diseases is anticipated to drive the global biosimilar market.

Global Biosimilars Market - By Distribution Channel

On basis of the distribution channel, global biosimilar market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The retail pharmacies segment dominates the global biosimilars market by distribution channel.

Global Natural Fiber Composites Market - By Region

Geographically, global biosimilars market covers five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In terms of revenue, Europe dominated the global biosimilars market in 2021 and is expected to maintain its dominance during the forecast period. Europe accounts for about half of the market. The increased use of biosimilars in Europe has fueled market growth. Furthermore, regulatory authorities have played a significant role in the adoption of biosimilars by making appropriate and favorable changes toward biosimilar drug approval.

North America, on the other hand, is expected to grow at a rapid pace during the forecast period. The growing popularity of biosimilars in North America, as well as the presence of numerous market players in the region, are driving significant investments in biosimilar research, which is expected to drive the biosimilars market in the region.

Competitive Landscape

Global biosimilars market is fiercely competitive, with Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon., Bayer AG, AbbVie Inc., Allergan, Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, and Biogen. The key strategies used by these market leaders are new product launches, mergers & acquisitions, and alliances. To grow their market share, these companies are also focusing on investing in innovations, collaborations, and expansions.

Recent Development

In May 2022 - Biocon Biologics, along with Viatris Inc., launched Abevmy, a bevacizumab drug, in Canada. This drug is a biosimilar to Avastin, developed by Roche, and was approved by Health Canada for four oncology indications. The launch of this drug helped the company to further expand its oncology portfolio in Canada, thereby expanding patient access to cost-effective biologics for cancer treatment.
In September 2021 - Sandoz, a Novartis division, signed a commercialization agreement with Bio-Thera Solutions for the biosimilar BAT1706, bevacizumab. This agreement added to the Sandoz’s leading off-patent portfolio for oncology & helped in market expansion. The agreement helps the company to strike a perfect strategic balance between patient care and cost-effectiveness.

Scope of the Report

Attributes	Details
Years Considered	Historical Data – 2019–2022
	Base Year – 2022
	Estimated Year – 2023
	Forecast Period – 2023–2029
Facts Covered	Revenue in USD Billion
Market Coverage	North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Product/ Service Segmentation	Product, Disease Indication, Distribution Channel, Region
Key Players	Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon., Bayer AG, AbbVie Inc., Allergan, Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, Biogen.

By Product

Monoclonal Antibodies

Infliximab
Rituximab
Trastuzumab

Insulin
Interferon
Etanercept
Glucagon
Calcitonin

By Disease Indication

Cancer
Auto Immune Diseases
Chronic Diseases
Blood Disorders
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

- North America
- Europe
- Asia Pacific (APAC)
- Latin America
- Middle East and Africa (MEA)

Research Framework
1. Research Objective
2. Product Overview
3. Market Segmentation
Executive Summary
Global Biosimilars Market Insights
1. Industry Value Chain Analysis
2. DROC Analysis
  1. Growth Drivers
    1. Rising prevalence of autoimmune diseases
    2. Increasing adoption of biosimilars
    3. Rising cost effectiveness of biosimilars
  2. Restraints
    1. Complexities in manufacturing
  3. Opportunity
    1. Rising research and development proficiencies
    2. Rising government investments on healthcare infrastructure
  4. Challenges
    1. Intense Competition
    2. High cost of R&D
3. Technology Advancements/Recent Developments
4. Regulatory Framework
5. Porter’s Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of New Entrants
  4. Threat of Substitutes
  5. Intensity of Rivalry
Global Biosimilars Market Overview
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product
    1. Monoclonal Antibodies
      1. Infliximab
      2. Rituximab
      3. Trastuzumab
    2. Insulin
    3. Interferon
    4. Etanercept
    5. Glucagon
    6. Calcitonin
  2. By Disease Indication
    1. Cancer
    2. Auto-Immune Diseases
    3. Chronic Diseases
    4. Blood Disorders
    5. Others
  3. By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  4. By Region
    1. North America
    2. Europe
    3. Asia Pacific (APAC)
    4. Latin America
    5. Middle East and Africa (MEA)
North America Biosimilars Market
1. 1. Market Size & Forecast, 2019–2029
  2. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product
  2. By Disease Indication
  3. By Distribution Channel
  4. By Country
    1. United States
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    2. Canada
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
Europe Biosimilars Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product
  2. By Disease Indication
  3. By Distribution Channel
  4. By Country
    1. Germany
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    2. United Kingdom
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    3. Italy
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    4. France
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    5. Spain
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    6. The Netherlands
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    7. Belgium
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    8. NORDIC Countries
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    9. Rest of Europe
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
Asia Pacific Biosimilars Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product
  2. By Disease Indication
  3. By Distribution Channel
  4. By Country
    1. China
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    2. India
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    3. Japan
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    4. South Korea
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    5. Australia & New Zealand
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    6. Indonesia
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    7. Malaysia
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    8. Singapore
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    9. Philippines
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    10. Vietnam
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    11. Rest of Asia Pacific
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
Latin America Biosimilars Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product
  2. By Disease Indication
  3. By Distribution Channel
  4. By Country
    1. Brazil
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    2. Mexico
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    3. Argentina
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    4. Peru
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    5. Colombia
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    6. Rest of Latin America
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
Middle East & Africa Biosimilars Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product
  2. By Disease Indication
  3. By Distribution Channel
  4. By Country
    1. Saudi Arabia
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    2. UAE
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    3. Qatar
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    4. Kuwait
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    5. Iran
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    6. South Africa
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    7. Nigeria
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    8. Kenya
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    9. Egypt
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    10. Morocco
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    11. Algeria
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
    12. Rest of Middle East & Africa
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
Competitive Landscape
1. List of Key Players and Their Offerings
2. Global Biosimilars Company Market Share Analysis, 2022
3. Competitive Benchmarking, By Operating Parameters
4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, and others)
Impact of Covid-19 on Global Biosimilars Market
Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
1. Novartis AG
2. Orion Pharma AB
3. Pfizer Inc.
4. Samsung Bioepis
5. Coherus BioSciences, Inc.
6. Amgen Inc.
7. Eli Lilly and Company.
8. Takeda Pharmaceutical Company Limited
9. Bristol-Myers Squibb Company
10. Merck KGaA
11. Teva Pharmaceutical Industries Ltd.
12. Biocon
13. Bayer AG
14. AbbVie Inc.
15. Allergan
16. Dr. Reddy’s Laboratories Ltd.
17. Boehringer Ingelheim International GmbH
18. Biogen
19. Other Prominent Players
Key Strategic Recommendations
Research Methodology
1. Qualitative Research
  1. Primary & Secondary Research
2. Quantitative Research
3. Market Breakdown & Data Triangulation
  1. Secondary Research
  2. Primary Research
4. Breakdown of Primary Research Respondents, By Region
5. Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.

List of Figures

Figure 1 Global Biosimilars Market Segmentation

Figure 2 Global Biosimilars Market Value Chain Analysis

Figure 3 Company Market Share Analysis, 2022

Figure 4 Global Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 5 Global Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 6 Global Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 7 Global Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 8 Global Biosimilars Market Share, By Region, By Value, 2019–2029

Figure 9 North America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 10 North America Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 11 North America Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 12 North America Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 13 North America Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 14 United States Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 15 United States Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 16 United States Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 17 United States Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 18 Canada Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 19 Canada Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 20 Canada Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 21 Canada Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 22 Europe Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 23 Europe Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 24 Europe Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 25 Europe Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 26 Europe Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 27 Germany Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 28 Germany Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 29 Germany Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 30 Germany Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 31 UK Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 32 UK Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 33 UK Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 34 UK Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 35 Italy Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 36 Italy Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 37 Italy Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 38 Italy Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 39 France Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 40 France Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 41 France Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 42 France Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 43 Spain Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 44 Spain Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 45 Spain Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 46 Spain Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 47 The Netherlands Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 48 The Netherlands Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 49 The Netherlands Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 50 The Netherlands Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 51 Belgium Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 52 Belgium Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 53 Belgium Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 54 Belgium Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 55 NORDIC Countries Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 56 NORDIC Countries Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 57 NORDIC Countries Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 58 NORDIC Countries Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 59 Rest of Europe Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 60 Rest of Europe Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 61 Rest of Europe Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 62 Rest of Europe Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 63 Asia-Pacific Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 64 Asia-Pacific Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 65 Asia-Pacific Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 66 Asia-Pacific Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 67 Asia-Pacific Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 68 China Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 69 China Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 70 China Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 71 China Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 72 India Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 73 India Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 74 India Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 75 India Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 76 Japan Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 77 Japan Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 78 Japan Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 79 Japan Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 80 South Korea Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 81 South Korea Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 82 South Korea Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 83 South Korea Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 84 Australia & New Zealand Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 85 Australia & New Zealand Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 86 Australia & New Zealand Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 87 Australia & New Zealand Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 88 Indonesia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 89 Indonesia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 90 Indonesia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 91 Indonesia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 92 Malaysia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 93 Malaysia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 94 Malaysia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 95 Malaysia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 96 Singapore Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 97 Singapore Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 98 Singapore Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 99 Singapore Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 100 Philippines Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 101 Philippines Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 102 Philippines Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 103 Philippines Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 104 Vietnam Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 105 Vietnam Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 106 Vietnam Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 107 Vietnam Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 108 Rest of APAC Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 109 Rest of APAC Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 110 Rest of APAC Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 111 Rest of APAC Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 112 Latin America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 113 Latin America Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 114 Latin America Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 115 Latin America Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 116 Latin America Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 117 Brazil Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 118 Brazil Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 119 Brazil Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 120 Brazil Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 121 Mexico Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 122 Mexico Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 123 Mexico Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 124 Mexico Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 125 Argentina Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 126 Argentina Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 127 Argentina Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 128 Argentina Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 129 Peru Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 130 Peru Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 131 Peru Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 132 Peru Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 133 Colombia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 134 Colombia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 135 Colombia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 136 Colombia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 137 Rest of LATAM Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 138 Rest of LATAM Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 139 Rest of LATAM Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 140 Rest of LATAM Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 141 Middle East & Africa Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 142 Middle East & Africa Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 143 Middle East & Africa Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 144 Middle East & Africa Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 145 Middle East & Africa Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 146 Saudi Arabia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 147 Saudi Arabia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 148 Saudi Arabia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 149 Saudi Arabia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 150 UAE Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 151 UAE Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 152 UAE Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 153 UAE Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 154 Qatar Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 155 Qatar Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 156 Qatar Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 157 Qatar Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 158 Kuwait Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 159 Kuwait Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 160 Kuwait Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 161 Kuwait Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 162 Iran Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 163 Iran Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 164 Iran Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 165 Iran Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 166 South Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 167 South Africa Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 168 South Africa Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 169 South Africa Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 170 Nigeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 171 Nigeria Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 172 Nigeria Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 173 Nigeria Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 174 Kenya Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 175 Kenya Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 176 Kenya Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 177 Kenya Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 178 Egypt Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 179 Egypt Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 180 Egypt Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 181 Egypt Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 182 Morocco Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 183 Morocco Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 184 Morocco Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 185 Morocco Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 186 Algeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 187 Algeria Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 188 Algeria Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 189 Algeria Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 190 Rest of Middle East & Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 191 Rest of Middle East & Africa Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 192 Rest of Middle East & Africa Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 193 Rest of Middle East & Africa Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

List of Tables

Table 1 Global Biosimilars Market Size, By Product, By Value, 2019–2029

Table 2 Global Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 3 Global Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 4 Global Biosimilars Market Size, By Region, By Value, 2019–2029

Table 5 North America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 6 North America Biosimilars Market Size, By Product, By Value, 2019–2029

Table 7 North America Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 8 North America Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 9 North America Biosimilars Market Size, By Country, By Value, 2019–2029

Table 10 United States Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 11 United States Biosimilars Market Size, By Product, By Value, 2019–2029

Table 12 United States Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 13 United States Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 14 Canada Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 15 Canada Biosimilars Market Size, By Product, By Value, 2019–2029

Table 16 Canada Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 17 Canada Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 18 Europe Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 19 Europe Biosimilars Market Size, By Product, By Value, 2019–2029

Table 20 Europe Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 21 Europe Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 22 Europe Biosimilars Market Size, By Country, By Value, 2019–2029

Table 23 Germany Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 24 Germany Biosimilars Market Size, By Product, By Value, 2019–2029

Table 25 Germany Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 26 Germany Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 27 UK Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 28 UK Biosimilars Market Size, By Product, By Value, 2019–2029

Table 29 UK Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 30 UK Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 31 Italy Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 32 Italy Biosimilars Market Size, By Product, By Value, 2019–2029

Table 33 Italy Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 34 Italy Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 35 France Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 36 France Biosimilars Market Size, By Product, By Value, 2019–2029

Table 37 France Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 38 France Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 39 Spain Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 40 Spain Biosimilars Market Size, By Product, By Value, 2019–2029

Table 41 Spain Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 42 Spain Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 43 The Netherlands Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 44 The Netherlands Biosimilars Market Size, By Product, By Value, 2019–2029

Table 45 The Netherlands Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 46 The Netherlands Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 47 Belgium Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 48 Belgium Biosimilars Market Size, By Product, By Value, 2019–2029

Table 49 Belgium Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 50 Belgium Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 51 NORDIC Countries Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 52 NORDIC Countries Biosimilars Market Size, By Product, By Value, 2019–2029

Table 53 NORDIC Countries Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 54 NORDIC Countries Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 55 Rest of Europe Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 56 Rest of Europe Biosimilars Market Size, By Product, By Value, 2019–2029

Table 57 Rest of Europe Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 58 Rest of Europe Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 59 Asia-Pacific Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 60 Asia-Pacific Biosimilars Market Size, By Product, By Value, 2019–2029

Table 61 Asia-Pacific Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 62 Asia-Pacific Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 63 Asia-Pacific Biosimilars Market Size, By Country, By Value, 2019–2029

Table 64 China Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 65 China Biosimilars Market Size, By Product, By Value, 2019–2029

Table 66 China Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 67 China Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 68 India Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 69 India Biosimilars Market Size, By Product, By Value, 2019–2029

Table 70 India Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 71 India Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 72 Japan Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 73 Japan Biosimilars Market Size, By Product, By Value, 2019–2029

Table 74 Japan Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 75 Japan Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 76 South Korea Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 77 South Korea Biosimilars Market Size, By Product, By Value, 2019–2029

Table 78 South Korea Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 79 South Korea Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 80 Australia & New Zealand Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 81 Australia & New Zealand Biosimilars Market Size, By Product, By Value, 2019–2029

Table 82 Australia & New Zealand Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 83 Australia & New Zealand Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 84 Indonesia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 85 Indonesia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 86 Indonesia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 87 Indonesia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 88 Malaysia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 89 Malaysia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 90 Malaysia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 91 Malaysia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 92 Singapore Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 93 Singapore Biosimilars Market Size, By Product, By Value, 2019–2029

Table 94 Singapore Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 95 Singapore Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 96 Philippines Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 97 Philippines Biosimilars Market Size, By Product, By Value, 2019–2029

Table 98 Philippines Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 99 Philippines Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 100 Vietnam Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 101 Vietnam Biosimilars Market Size, By Product, By Value, 2019–2029

Table 102 Vietnam Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 103 Vietnam Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 104 Rest of APAC Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 105 Rest of APAC Biosimilars Market Size, By Product, By Value, 2019–2029

Table 106 Rest of APAC Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 107 Rest of APAC Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 108 Latin America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 109 Latin America Biosimilars Market Size, By Product, By Value, 2019–2029

Table 110 Latin America Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 111 Latin America Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 112 Latin America Biosimilars Market Size, By Country, By Value, 2019–2029

Table 113 Brazil Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 114 Brazil Biosimilars Market Size, By Product, By Value, 2019–2029

Table 115 Brazil Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 116 Brazil Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 117 Mexico Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 118 Mexico Biosimilars Market Size, By Product, By Value, 2019–2029

Table 119 Mexico Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 120 Mexico Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 121 Argentina Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 122 Argentina Biosimilars Market Size, By Product, By Value, 2019–2029

Table 123 Argentina Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 124 Argentina Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 125 Peru Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 126 Peru Biosimilars Market Size, By Product, By Value, 2019–2029

Table 127 Peru Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 128 Peru Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 129 Colombia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 130 Colombia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 131 Colombia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 132 Colombia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 133 Rest of LATAM Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 134 Rest of LATAM Biosimilars Market Size, By Product, By Value, 2019–2029

Table 135 Rest of LATAM Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 136 Rest of LATAM Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 137 Middle East & Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 138 Middle East & Africa Biosimilars Market Size, By Product, By Value, 2019–2029

Table 139 Middle East & Africa Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 140 Middle East & Africa Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 141 Middle East & Africa Biosimilars Market Size, By Country, By Value, 2019–2029

Table 142 Saudi Arabia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 143 Saudi Arabia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 144 Saudi Arabia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 145 Saudi Arabia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 146 UAE Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 147 UAE Biosimilars Market Size, By Product, By Value, 2019–2029

Table 148 UAE Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 149 UAE Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 150 Qatar Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 151 Qatar Biosimilars Market Size, By Product, By Value, 2019–2029

Table 152 Qatar Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 153 Qatar Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 154 Kuwait Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 155 Kuwait Biosimilars Market Size, By Product, By Value, 2019–2029

Table 156 Kuwait Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 157 Kuwait Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 158 Iran Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 159 Iran Biosimilars Market Size, By Product, By Value, 2019–2029

Table 160 Iran Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 161 Iran Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 162 South Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 163 South Africa Biosimilars Market Size, By Product, By Value, 2019–2029

Table 164 South Africa Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 165 South Africa Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 166 Nigeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 167 Nigeria Biosimilars Market Size, By Product, By Value, 2019–2029

Table 168 Nigeria Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 169 Nigeria Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 170 Kenya Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 171 Kenya Biosimilars Market Size, By Product, By Value, 2019–2029

Table 172 Kenya Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 173 Kenya Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 174 Egypt Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 175 Egypt Biosimilars Market Size, By Product, By Value, 2019–2029

Table 176 Egypt Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 177 Egypt Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 178 Morocco Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 179 Morocco Biosimilars Market Size, By Product, By Value, 2019–2029

Table 180 Morocco Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 181 Morocco Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 182 Algeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 183 Algeria Biosimilars Market Size, By Product, By Value, 2019–2029

Table 184 Algeria Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 185 Algeria Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 186 Rest of Middle East & Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 187 Rest of Middle East & Africa Biosimilars Market Size, By Product, By Value, 2019–2029

Table 188 Rest of Middle East & Africa Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 189 Rest of Middle East & Africa Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 190 Novartis AG Company Overview

Table 191 Novartis AG Financial Overview

Table 192 Orion Pharma AB Company Overview

Table 193 Orion Pharma AB Financial Overview

Table 194 Pfizer Inc. Company Overview

Table 195 Pfizer Inc. Financial Overview

Table 196 Samsung Bioepis Company Overview

Table 197 Samsung Bioepis Financial Overview

Table 198 Coherus BioSciences, Inc. Company Overview

Table 199 Coherus BioSciences, Inc. Financial Overview

Table 200 Amgen Inc. Company Overview

Table 201 Amgen Inc. Financial Overview

Table 202 Eli Lilly and Company Overview

Table 203 Eli Lilly and Company Financial Overview

Table 204 Takeda Pharmaceutical Company Limited Company Overview

Table 205 Takeda Pharmaceutical Company Limited Financial Overview

Table 206 Bristol-Myers Squibb Company Overview

Table 207 Bristol-Myers Squibb Company Financial Overview

Table 208 Merck KGaA Company Overview

Table 209 Merck KGaA Financial Overview

Table 210 Teva Pharmaceutical Industries Ltd. Company Overview

Table 211 Teva Pharmaceutical Industries Ltd. Financial Overview

Table 212 Biocon Company Overview

Table 213 Biocon Financial Overview

Table 214 Bayer AG Company Overview

Table 215 Bayer AG Financial Overview

Table 216 AbbVie Inc. Company Overview

Table 217 AbbVie Inc. Financial Overview

Table 218 Allergan Company Overview

Table 219 Allergan Financial Overview

Table 220 Dr. Reddy’s Laboratories Ltd. Company Overview

Table 221 Dr. Reddy’s Laboratories Ltd. Financial Overview

Table 222 Boehringer Ingelheim International GmbH Company Overview

Table 223 Boehringer Ingelheim International GmbH Financial Overview

Table 224 Biogen Company Overview

Table 225 Biogen Financial Overview

Market Segmentation

By Product

Monoclonal Antibodies

Infliximab
Rituximab
Trastuzumab

Insulin
Interferon
Etanercept
Glucagon
Calcitonin

By Disease Indication

Cancer
Auto Immune Diseases
Chronic Diseases
Blood Disorders
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

- North America
- Europe
- Asia Pacific (APAC)
- Latin America
- Middle East and Africa (MEA)

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

1. What is the current market size of Global Biosimilars Market?

Ans: Global Biosimilars Market size is estimated at 28.88 billion in 2022.

2. What are the major factors driving the growth of the Global Biosimilars Market?

Ans: Major factors driving the growth of Global Biosimilars Market include rising autoimmune disease prevalence, rising biosimilar adoption, rising biosimilar cost-effectiveness, rising research and development skills, and rising government spending on healthcare infrastructure.

3. Which distribution channel segment is the dominant one in Global Biosimilars Market

Ans: The retail pharmacies segment holds the highest market share in the Global Biosimilars Market by distribution channel.

4. Which product segment accounts for the highest share in Global Biosimilars Market?

Ans: The monoclonal antibodies segment accounts for the highest market share in the global biosimilars market by product.

5. Name the key players in Global Biosimilars Market.

Ans: Key players in Global Biosimilars Market include Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon., Bayer AG, AbbVie Inc., Allergan, Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, and Biogen.

PLACE AN ORDER

SINGLE USER LICENSE
$ 4450
GROUP LICENSE
$ 5550
ENTERPRISE LICENSE
$ 7850

Request for Sample

RELATED REPORTS

WHY CHOOSE US

24/7 Research Support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Custom Research Service

Ask the Analyst to customize an exclusive study to serve your research needs
Quality & Accuracy

Ask the Analyst to customize an exclusive study to serve your research needs
Data Visualization

As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
Information security

We never share your personal and confidential information. Your personal information is safe and secure with us.

Global Biosimilars Market

Report Overview

Market Segmentation

To request a free sample copy of this report, please complete the form below.

Frequently Asked Questions (FAQs):

1. What is the current market size of Global Biosimilars Market?

2. What are the major factors driving the growth of the Global Biosimilars Market?

3. Which distribution channel segment is the dominant one in Global Biosimilars Market

4. Which product segment accounts for the highest share in Global Biosimilars Market?

5. Name the key players in Global Biosimilars Market.

PLACE AN ORDER

RELATED REPORTS

WHY CHOOSE US

24/7 Research Support

Custom Research Service

Quality & Accuracy

Data Visualization

Information security